IMR Press / FBE / Volume 3 / Issue 2 / DOI: 10.2741/E280

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

CD133 negative cancer stem cells in glioblastoma
Show Less
1 Department of Neurology, RWTH Aachen, Pauwelsstrasse 30, 52074 Aachen

*Author to whom correspondence should be addressed.

Academic Editor: Manuel Verdugo

Front. Biosci. (Elite Ed) 2011, 3(2), 701–710;
Published: 1 January 2011
(This article belongs to the Special Issue Initiation of DNA replication)

Glioblastomas (GBM) are paradigmatic for the investigation of cancer stem cells (CSC) in solid tumors. Recently, the discovery of CD133- CSC in addition to CD133+ CSC has substantially added to our understanding of the complexity of GBM CSC. This review gives an overview on our current knowledge on CD133- cells in GBM and describes five different hypothesizes on the nature of CD133- cells in GBM. In addition, we summarize the current knowledge on tumorigenic CD133- CSC, list available markers, describe the current controversies on the origin of CD133- CSC, and discuss how the heterogeneity of CSC may correspond to the molecular heterogeneity of GBM.

Cancer Stem Cell
Transcriptional Profile
Back to top